Type II diabetes mellitus is a known cardiovascular risk factor and its prevalence continues to increase. A revolution in the Type II diabetes mellitus treatment has occurred with the arrival of new antidiabetic drugs, which are thought to compromise metformin place. We aim to review the pharmacology, available evidence and clinical aspects of metformin use in the era of new antidiabetics.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fca-2020-0195 | DOI Listing |
Publication Analysis
Top Keywords
metformin era
8
era antidiabetics
8
type diabetes
8
diabetes mellitus
8
antidiabetics type
4
mellitus cardiovascular
4
cardiovascular risk
4
risk factor
4
factor prevalence
4
prevalence continues
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!